AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29783095 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine treatment initiated after release
Number of subjects: 199
Study 29783095 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 199
Study 27430210 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (Riastap®) 60-70 mg/kg
Number of subjects: 40
Study 27430210 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 40
Study 25164471 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical therapy (3 sessions/week for 24 weeks)
Number of subjects: 27
Study 25164471 — intervention group
Group type: COMPARATOR
Intervention: Controlled home-based program (same duration as supervised)
Number of subjects: 27
Study 25164471 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27
Study 22249344 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus QD
Number of subjects: 60
Study 22249344 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus BID
Number of subjects: 60
Study 22249344 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 60
Study 19843485 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg, step-down dosing: 21 mg for 6 weeks, then 14 mg and 7 mg for 2-week periods)
Number of subjects: 502
Study 19843485 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg)
Number of subjects: 502
Study 19843485 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 502
Study 17451401 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 10 to 40 mg
Number of subjects: 403
Study 17451401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study 14693628 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic posterior approach with 0.75% ropivacaine
Number of subjects: 75
Study 14693628 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified subgluteus posterior approach with 0.75% ropivacaine
Number of subjects: 75
Study 14693628 — intervention group
Group type: COMPARATOR
Intervention: Lateral popliteal approach with 0.75% ropivacaine
Number of subjects: 75
Study 14693628 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 75
Study 11800375 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 20
Study 11800375 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine-adrenaline solution (LA)
Number of subjects: 20
Study 9689392 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's and Infants Postoperative Pain Scale (CHIPPS)
Number of subjects: 139
Study 9689392 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants Postoperative Pain Scale (IPPS)
Number of subjects: 139
Study 9689392 — intervention group
Group type: EXPERIMENTAL
Intervention: Piritramide
Number of subjects: 139
Study 9689392 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 139
Study 9689392 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 139
Study 9689392 — intervention group
Group type: COMPARATOR
Intervention: CHIPPS vs IPPS
Number of subjects: 139
Study 8133114 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine (0.25 mg of base/kg of body weight/day over 14 days)
Number of subjects: 85
Study 8133114 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (25 mg of base/kg over 3 days)
Number of subjects: 85
Study 8133114 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chloroquine-primaquine
Number of subjects: 85
Study 2550245 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin 0.125 U.kg-1 + placebo
Number of subjects: 8
Study 2550245 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP 100 micrograms + placebo
Number of subjects: 8
Study 2550245 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin + hANP
Number of subjects: 8
Study 2550245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 789791 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional A/England/42/72 (H3N2) vaccine (X‐37)
Number of subjects: 0
Study 789791 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigenic hybrid (Heq1N2) vaccine (X‐38)
Number of subjects: 0
Study 789791 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 0
Study 30302915 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy-framed implementation intentions
Number of subjects: 300
Study 30302915 — intervention group
Group type: COMPARATOR
Intervention: Control-framed implementation intentions
Number of subjects: 300
Study 27692565 — intervention group
Group type: EXPERIMENTAL
Intervention: Crofelemer
Number of subjects: 46
Study 27692565 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 46
Study 26165176 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma cis-lutein/zeaxanthin levels at 3 months
Number of subjects: 39
Study 26165176 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma α-tocopherol levels at 3 months
Number of subjects: 39
Study 26165176 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma β-cryptoxanthin levels at 3 months
Number of subjects: 39
Study 26165176 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma all-trans-lycopene levels at 3 months
Number of subjects: 39
Study 26165176 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent increase in α-tocopherol levels from baseline to month 3
Number of subjects: 39
Study 26165176 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent increase in trans-β-carotene levels from baseline to month 3
Number of subjects: 39
Study 26165176 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent increase in β-cryptoxanthin levels from baseline to month 3
Number of subjects: 39
Study 26165176 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent increase in cis-lutein/zeaxanthin levels from baseline to month 3
Number of subjects: 39
Study 26165176 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent increase in all-trans-lycopene levels from baseline to month 3
Number of subjects: 39
Study 23701469 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow eccentric exercise (30° s(‐1))
Number of subjects: 17
Study 23701469 — intervention group
Group type: COMPARATOR
Intervention: Fast eccentric exercise (210° s(‐1))
Number of subjects: 17
Study 23701469 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (slow and fast eccentric exercise)
Number of subjects: 17
Study 22167767 — intervention group
Group type: EXPERIMENTAL
Intervention: N(2)-L-alanyl-L-glutamine (GLN) 0.4 g/kg per day
Number of subjects: 50
Study 22167767 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 50
Study 19484969 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemic-hyperinsulinemic clamp after 2 week insulin intensive treatment
Number of subjects: 16
Study 19484969 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (NC)
Number of subjects: 16
Study 19484969 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (T2DM)
Number of subjects: 16
Study 16377979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribose supplementation (10 g in 8 oz water)
Number of subjects: 31
Study 16377979 — intervention group
Group type: COMPARATOR
Intervention: Dextrose supplementation (10 g in 8 oz water)
Number of subjects: 31
Study 12928639 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariporide 120 mg
Number of subjects: 2998
Study 12928639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2998
Study 10949007 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO/PRO/FAT
Number of subjects: 10
Study 10949007 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO
Number of subjects: 10
Study 10949007 — intervention group
Group type: COMPARATOR
Intervention: PL
Number of subjects: 10
Study 8846273 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5% Human albumin solution (HAS) (mean volume 25.6 ml.kg‐1, SD 9.5)
Number of subjects: 30
Study 8846273 — intervention group
Group type: COMPARATOR
Intervention: Haemaccel (Hoechst) (24.9 ml.kg‐1, SD 10)
Number of subjects: 30
Study 1506807 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 0
Study 1506807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6380336 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 20 mg
Number of subjects: 52
Study 30376537 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (LDK) at 2.5 μg·kg·min for 48 hours
Number of subjects: 91
Study 30376537 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (LDK)
Number of subjects: 91
Study 30376537 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline at equivalent rate for 48 hours)
Number of subjects: 91
Study 30376537 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline)
Number of subjects: 91
Study 30471966 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Ai Chi (50min)
Number of subjects: 18
Study 30471966 — intervention group
Group type: COMPARATOR
Intervention: Conventional aquatic therapy (50min)
Number of subjects: 18
Study 27921201 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency group (n = 37)
Number of subjects: 37
Study 27921201 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate group (n = 17)
Number of subjects: 37
Study 27921201 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency group (n = 17)
Number of subjects: 37
Study 27921201 — intervention group
Group type: COMPARATOR
Intervention: Low scorers cluster (n = 136)
Number of subjects: 37
Study 27921201 — intervention group
Group type: COMPARATOR
Intervention: High scorers cluster (n = 26)
Number of subjects: 37
Study 25459890 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoallopregnanolone (ISO) administered in combination with Allopregnanolone (AP)
Number of subjects: 12
Study 25459890 — intervention group
Group type: COMPARATOR
Intervention: Allopregnanolone (AP) alone
Number of subjects: 12
Study 25459890 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoallopregnanolone (ISO) at a dose approximately half of AP
Number of subjects: 12
Study 23412004 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (25 µg every 2 hours for up to 24 hours)
Number of subjects: 260
Study 23412004 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (10 IU infusion gradually increased)
Number of subjects: 260
Study 23412004 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 260
Study 21600042 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation with additional bone graft substitute
Number of subjects: 39
Study 21600042 — intervention group
Group type: COMPARATOR
Intervention: Internal fixation only
Number of subjects: 39
Study 18633421 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal massage therapy (standard care plus maternal massage performed four times a day on the face and limbs)
Number of subjects: 104
Study 18633421 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal massage therapy
Number of subjects: 104
Study 16758751 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon and ribavirin combination therapy
Number of subjects: 0
Study 16758751 — intervention group
Group type: COMPARATOR
Intervention: two brands of peginterferon
Number of subjects: 0
Study 15022864 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-enhanced training
Number of subjects: 99
Study 15022864 — intervention group
Group type: COMPARATOR
Intervention: Standard training
Number of subjects: 99
Study 11309871 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg intra-nasal midazolam
Number of subjects: 38
Study 11309871 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg intra-nasal midazolam
Number of subjects: 38
Study 11309871 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg intra-nasal midazolam
Number of subjects: 38
Study 11309871 — intervention group
Group type: COMPARATOR
Intervention: Fasting condition
Number of subjects: 38
Study 11309871 — intervention group
Group type: COMPARATOR
Intervention: Non-fasting condition
Number of subjects: 38
Study 9278832 — intervention group
Group type: EXPERIMENTAL
Intervention: Double lumen i.v. set (DLIS)
Number of subjects: 50
Study 9278832 — intervention group
Group type: COMPARATOR
Intervention: Single lumen i.v. set (SLIS)
Number of subjects: 50
Study 8511732 — intervention group
Group type: EXPERIMENTAL
Intervention: Solenoid valve
Number of subjects: 12
Study 8511732 — intervention group
Group type: COMPARATOR
Intervention: Weighted plunger
Number of subjects: 12
Study 3549805 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% minoxidil
Number of subjects: 60
Study 3549805 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% minoxidil
Number of subjects: 60
Study 3549805 — intervention group
Group type: COMPARATOR
Intervention: Placebo (crossover to 3% minoxidil)
Number of subjects: 60
Study 31652075 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal feedback
Number of subjects: 120
Study 31652075 — intervention group
Group type: EXPERIMENTAL
Intervention: Written feedback
Number of subjects: 120
Study 31652075 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine method)
Number of subjects: 120
Study 29309385 — intervention group
Group type: EXPERIMENTAL
Intervention: Freak Bar (FB)
Number of subjects: 10
Study 29309385 — intervention group
Group type: COMPARATOR
Intervention: Traditional Barbell (TB)
Number of subjects: 10
Study 27804269 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 100
Study 24596968 — intervention group
Group type: EXPERIMENTAL
Intervention: Enjoy eating program (15 weeks)
Number of subjects: 20
Study 24520741 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 100
Study 24520741 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 100
Study 21396089 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet based self-help intervention for sub-clinical and mild PD
Number of subjects: 128
Study 21396089 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 128
Study 18500155 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX‐T varnish (six applications every 15 days for 75 days)
Number of subjects: 57
Study 18500155 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish (six applications every 15 days for 75 days)
Number of subjects: 57
Study 16594879 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (12 weeks, 3 times per week, 30 minutes each session)
Number of subjects: 75
Study 16594879 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group 1)
Number of subjects: 75
Study 16594879 — intervention group
Group type: COMPARATOR
Intervention: Social visit (control group 2)
Number of subjects: 75
Study 15088900 — intervention group
Group type: EXPERIMENTAL
Intervention: NMP 22 Test
Number of subjects: 164
Study 15088900 — intervention group
Group type: COMPARATOR
Intervention: Urine cytology
Number of subjects: 164
Study 11120507 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole gel
Number of subjects: 75
Study 11120507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 9361167 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily (OM20)
Number of subjects: 994
Study 9361167 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg once daily (OM10)
Number of subjects: 994
Study 9361167 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily (RAN)
Number of subjects: 994
Study 8263387 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal pack retained for 24 hours
Number of subjects: 180
Study 8263387 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal pack retained for 48 hours
Number of subjects: 180
Study 8263387 — intervention group
Group type: COMPARATOR
Intervention: No nasal pack
Number of subjects: 180
Study 3725890 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofensine (50 mg single morning dose)
Number of subjects: 107
Study 3725890 — intervention group
Group type: COMPARATOR
Intervention: Nomifensine (75-100 mg in two divided doses)
Number of subjects: 107
Study 31060106 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of Daily Living (ADL) I (without disability)
Number of subjects: 84
Study 31060106 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of Daily Living (ADL) II (disabled only in some instrumental ADL)
Number of subjects: 84
Study 31060106 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of Daily Living (ADL) III (disabled in some basic ADL)
Number of subjects: 84
Study 31060106 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment outcomes for all patients
Number of subjects: 84
Study 29776750 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-DT (25 µg) administered at 0 and 4 weeks
Number of subjects: 144
Study 29776750 — intervention group
Group type: COMPARATOR
Intervention: Typhim Vi® (first dose) and Vaxigrip® (second dose)
Number of subjects: 144
Study 29776750 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-DT
Number of subjects: 144
Study 27245206 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactogogue containing silymarin-phosphatidylserine and galega, 5 g/day (galactogogue group, GG)
Number of subjects: 100
Study 27245206 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 5 g of lactose per day (placebo group, PG)
Number of subjects: 100
Study 25293975 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended implementation strategy (visits from a guideline facilitator, stratification tools, feedback on guideline adherence)
Number of subjects: 1200
Study 25293975 — intervention group
Group type: COMPARATOR
Intervention: Usual implementation
Number of subjects: 1200
Study 25293975 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended implementation strategy
Number of subjects: 1200
Study 22284244 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD)
Number of subjects: 27
Study 22284244 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet + Exercise (VLCD+E)
Number of subjects: 27
Study 22284244 — intervention group
Group type: COMPARATOR
Intervention: Control (Healthy Lean and Obese)
Number of subjects: 27
Study 16019863 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully Included (FI) students with CP
Number of subjects: 248
Study 16019863 — intervention group
Group type: COMPARATOR
Intervention: Typical Students (TS)
Number of subjects: 248
Study 16019863 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Contained (SC) students with CP
Number of subjects: 248
Study 16019863 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity performance
Number of subjects: 248
Study 12124548 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (5000 U/kg)
Number of subjects: 22
Study 9846707 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin plus amniotomy
Number of subjects: 320
Study 9846707 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal PGE2 2 mg, two doses at 6-hour intervals
Number of subjects: 320
Study 9846707 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 320
Study 7813723 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin injected into a central venous line 5 minutes before infrarenal aortic clamping (Group I)
Number of subjects: 26
Study 7813723 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin injected into the distal aneurysm immediately after infrarenal aortic clamping (Group II)
Number of subjects: 26
Study 7813723 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin injected into a central venous line immediately after infrarenal aortic clamping (Group III)
Number of subjects: 26
Study 2676647 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate 1.5 g twice daily
Number of subjects: 43
Study 2676647 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg after evening meal
Number of subjects: 43
Study 931293 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids equipped with directional microphones
Number of subjects: 0
Study 931293 — intervention group
Group type: COMPARATOR
Intervention: Hearing aids equipped with omni-directional microphones
Number of subjects: 0
Study 29523560 — intervention group
Group type: EXPERIMENTAL
Intervention: Family group conferences
Number of subjects: 328
Study 27560161 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol at 1000 IU/day for 2 months
Number of subjects: 80
Study 27560161 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D levels in patients with acne
Number of subjects: 80
Study 25057153 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding (140% of baseline energy requirements for 56 days)
Number of subjects: 0
Study 22309784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 22309784 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg gabapentin
Number of subjects: 100
Study 22309784 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg gabapentin
Number of subjects: 100
Study 20502641 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral polio vaccine (OPV) with BCG
Number of subjects: 0
Study 20502641 — intervention group
Group type: COMPARATOR
Intervention: BCG only
Number of subjects: 0
Study 17852673 — intervention group
Group type: EXPERIMENTAL
Intervention: Toe-clip pedals
Number of subjects: 11
Study 17852673 — intervention group
Group type: COMPARATOR
Intervention: Flat pedals
Number of subjects: 11
Study 16253622 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness perceptions assessed within 24 hours of acute MI
Number of subjects: 194
Study 12396332 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric current perception threshold measurement
Number of subjects: 708
Study 10430977 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 2 g
Number of subjects: 495
Study 10430977 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 3 g
Number of subjects: 495
Study 10430977 — intervention group
Group type: COMPARATOR
Intervention: AZA
Number of subjects: 495
Study 7605950 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild negative emotional changes
Number of subjects: 0
Study 7605950 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild positive emotional changes
Number of subjects: 0